EUVIMEDEUVIMED entdecken
Crossref

4‐Octyl itaconate alleviates experimental autoimmune prostatitis by inhibiting the NLRP3 inflammasome‐induced pyroptosis through activating Nrf2/HO‐1 pathway

Xiaohu Zhao, Rui Feng, Juan Chen, Qing Jiang, Xiaoliang Hua, Chaozhao Liang iD

The Prostate · 2024

DOI: 10.1002/pros.24652 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Prostate, 2024. Verfasst von Xiaohu Zhao und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, China. Hauptthemen laut MEDLINE: Prostatitis, Diabetes Mellitus, Experimental, Succinates. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Chongqing Science and Technology, China Postdoctoral Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Chronic prostatitis demonstrates a prevalence rate of nearly 5%–10% among young and middle‐aged individuals, significantly affecting their daily lives. Researchers have obtained significant outcomes investigating the anti‐inflammatory properties of itaconic acid (IA) and its derivative, 4‐Octyl itaconate (4‐OI), against diverse chronic inflammatory disorders, such as osteoarthritis and airway inflammation. Nevertheless, whether IA can also exert anti‐inflammatory effects in chronic prostatitis requires extensive research and validation.

Methods

Human prostate tissues obtained through transurethral prostate resection (TURP) from individuals were divided into three groups based on different levels of inflammation using hematoxylin and eosin staining (H&E). Subsequently, immunohistochemistry (IHC) was employed to detect the expression of immune‐responsive gene 1 (IRG‐1) in these different groups. The animal experiment of this study induced experimental autoimmune prostatitis (EAP) in nonobese diabetic mice through intradermal prostate antigen injection and complete Freund's adjuvant. Then, the experimental group received intraperitoneal injections of different doses of 4‐OI, while the control group received injections of saline. Western blot (WB), H&E staining, and TUNEL staining helped analyze the prostate tissues, while enzyme‐linked immunosorbent assay (ELISA) helped evaluate serum inflammatory factors. Reactive oxygen species, superoxide dismutase (SOD), and malondialdehyde (MDA) were assessed for oxidative stress across experimental groups.

Results

IHC analysis of human prostate tissue depicts that IRG‐1 expression enhances as prostate inflammation worsens, highlighting the critical role of IA in human prostatitis. The application of 4‐OI increased Nrf2/HO‐1 expression while inhibited NLRP3 expression following the WB results, and its application resulted in a decrease in cell pyroptosis in prostate tissue, demonstrated by the results of TUNEL staining. Administering a Nrf2 inhibitor ML385 1 h before intraperitoneal injection of 50 mg/kg 4‐OI reversed the previous conclusion, further confirming the above conclusion from another perspective. Meanwhile, the ELISA results of serum inflammatory factors (IL‐1β, IL‐6, and TNF‐α), as well as the measurements of oxidative stress markers MDA and SOD, further confirmed the specific anti‐inflammatory effects of 4‐OI in EAP.

Conclusions

The present study indicates that 4‐OI can alleviates EAP by inhibiting the NLRP3 inflammasome‐induced pyroptosis through activating Nrf2/HO‐1 pathway, which may facilitate a novel approach toward prostatitis treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProstatitisDiabetes Mellitus, ExperimentalSuccinatesHumansMaleMiceAnimalsMiddle AgedInflammasomesNF-E2-Related Factor 2NLR Family, Pyrin Domain-Containing 3 ProteinPyroptosisChronic DiseaseInflammationAnti-Inflammatory AgentsSuperoxide Dismutase

Stichwörter der Autor:innen

4-Octyl itaconatechronic prostatitis and chronic pelvic pain syndrome (CP/CPPS)inflammationpyroptosis

Substanzen

Inflammasomes4-octyl itaconateNF-E2-Related Factor 2NLR Family, Pyrin Domain-Containing 3 Proteinitaconic acidAnti-Inflammatory AgentsSuperoxide DismutaseSuccinates

Autor:innen und Institutionen

  • Department of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
  • Department of Urology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
  • The Ministry of Education Key Laboratory of Laboratory Medical Diagnostics, The College of Laboratory Medicine, Chongqing Medical University, Chongqing, China.

ORCID-Profile: Chaozhao Liang

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Chongqing Science and Technology
  • China Postdoctoral Science Foundation

Zitieren

APA

Zhao, X., Feng, R., Chen, J., Jiang, Q., Hua, X., & Liang, C. (2024). 4‐Octyl itaconate alleviates experimental autoimmune prostatitis by inhibiting the NLRP3 inflammasome‐induced pyroptosis through activating Nrf2/HO‐1 pathway. The Prostate. https://doi.org/10.1002/pros.24652

Vancouver

Zhao X, Feng R, Chen J, Jiang Q, Hua X, Liang C. 4‐Octyl itaconate alleviates experimental autoimmune prostatitis by inhibiting the NLRP3 inflammasome‐induced pyroptosis through activating Nrf2/HO‐1 pathway. The Prostate. 2024. doi:10.1002/pros.24652

BibTeX
@article{Zhao2024,
  author = {Zhao, Xiaohu and Feng, Rui and Chen, Juan and Jiang, Qing and Hua, Xiaoliang and Liang, Chaozhao},
  title = {4‐Octyl itaconate alleviates experimental autoimmune prostatitis by inhibiting the NLRP3 inflammasome‐induced pyroptosis through activating Nrf2/HO‐1 pathway},
  journal = {The Prostate},
  year = {2024},
  doi = {10.1002/pros.24652}
}
Kostenlos starten →